National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

Similar documents
National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

- the details, where possible, of the antibiotic products these companies supply or have supplied.

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Antibiotics.

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

EUCAST recommended strains for internal quality control

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

2015 Antibiotic Susceptibility Report

Cephalosporins, Quinolones and Co-amoxiclav Prescribing Audit

2016 Antibiotic Susceptibility Report

Introduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience.

Quality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction

moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering

European Committee on Antimicrobial Susceptibility Testing

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

January 2014 Vol. 34 No. 1

Lyme disease: diagnosis and management

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review

Volume 1; Number 7 November 2007

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

MEDICATIONS MEXICO S DE R.L. DE C.V. Agrifen Acetaminophen Chlorpheniramine 40 # Amikacin Generic 500 mg 2ml 2 ampoules #

What s new in EUCAST methods?

3 party manufacturing PRODUCT LIST. Category : ANTI BIOTIC

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

Scottish Medicines Consortium

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS

European Committee on Antimicrobial Susceptibility Testing

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Advanced Practice Education Associates. Antibiotics

January 2014 Vol. 34 No. 1

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani

Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007

Streptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance

Rate In Rs.Ps (ED Included. Tax Extra) Sl No Name Of The Product Pack. Scheduled And Non-Scheduled Formulations Capsules

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

3/20/2011. Code 215 of Hammurabi: If a physician performed a major operation on

Antimicrobial Susceptibility Testing: Advanced Course

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Measure Information Form

Antibiotic Usage Guidelines in Hospital

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form

GENERAL NOTES: 2016 site of infection type of organism location of the patient

Choosing the Best Antibiotic in Problem Outpatient Infectious Disease Cases

AMR Industry Alliance Antibiotic Discharge Targets

Pneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center

OPAT discharge navigator and laboratory monitoring Select OPAT button for ALL patients that discharge on intravenous antimicrobials

Approach to pediatric Antibiotics

Antimicrobial Pharmacodynamics

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

Intro Who should read this document 2 Key practice points 2 Background 2

56 Clinical and Laboratory Standards Institute. All rights reserved.

Antimicrobial Susceptibility Testing: The Basics

Antibiotic Updates: Part II

Practical Notes on Antibiotics

SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

British Society for Antimicrobial Chemotherapy

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe

Penicillins - EUCAST clinical MIC breakpoints (version 1.3)

Community Acquired Pneumonia: An Update on Guidelines

Telephone Max dose amoxicillin pediatrics P.O. Box 189 Navan, ON, K4B 1J4 Canada. Sitemap

The UK 5-year AMR Strategy - a brief overview - Dr Berit Muller-Pebody National Infection Service Public Health England

UNDERSTANDING SOUTH AFRICA'S CONSUMPTION OF ANTIMICROBIALS

Lifting the lid off CAP guidelines

Responsible use of antibiotics

Intrinsic, implied and default resistance

Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report. July December 2013 Second and Third Quarters 2014

ß-lactams. Sub-families. Penicillins. Cephalosporins. Monobactams. Carbapenems

Doxycycline for strep pneumonia

Antibiotic Updates: Part I

Considerations in antimicrobial prescribing Perspective: drug resistance

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient

British Society for Antimicrobial Chemotherapy

Copyright 2012 Diabetes In Control, Inc. For permission to reprint, please contact Heather Moran, Production Editor, at

Studies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India

ICAAC. Key words: antibacterial agent development approval. linezolid β. chloramphenicol tetracycline colistin mupirocin teicoplanin

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

Antimicrobial susceptibility

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program

2017 Washington State Hospital Association 1 P a g e

St. Joseph s General Hospital Vegreville. and. Mary Immaculate Care Centre. Antimicrobial Stewardship Report

Preserve the Power of Antibiotics

UTI Dr S Mathijs Department of Pharmacology

Antimicrobial Therapy

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE

Antimicrobial Update Stewardship in Primary Care. Clare Colligan Antimicrobial Pharmacist NHS Forth Valley

Anti-infection Agents

Disclosures. Respiratory Infection and Antibiotics. What is the treatment of choice for ABRS? Acute Bacterial Rhinosinusitis

ANTIBIOTIC FORMULARY AND PRESCRIBING ADVICE FOR PAEDIATRIC PATIENTS OTHER THAN NEONATES

* gender factor (male=1, female=0.85)

High Risk Emergency Medicine. Antibiotic Pitfalls

Antibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?

Transcription:

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix O 3 December 2014 Final version Commissioned by the National Institute for Health and Care Excellence

Contents Disclaimer Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer. Copyright Funding National Institute for Health and Care Excellence

Contents 1... 5 2 References... 15 4

1 Table 1 - Cost of oral antibiotic therapy for pneumonia Beta-lactams Narrow spectrum class 1 Penicillin V 0.5 g every 6 tab 0.04 0.33 Narrow spectrum class 2 Ampicillin 0.25 g every 6 1 g every 6 tab 0.04 0.67 0.5 g every 6 250 mg/5 ml 100 ml (5 1 g every 6 250 mg/5 ml 100 ml (5 0.5 g every 6 250 mg/5 ml SF, 100 ml (5 1 g every 6 250mg/5 ml SF, 100 ml (5 0.5 g every 6 28 x 500 mg 1 g every 6 28 x 500 mg 0.5 g every 4 250 mg/5 ml 100 ml (5 0.5 g every 6 250mg/5 ml 100 ml (5 15.50 6.20 15.50 12.40 16.56 6.62 16.56 13.25 0.19 1.52 0.83 3.30 0.83 6.61 11.84 7.10 11.84 4.74 Amoxicillin 0.5 g every 8 21 x 500 mg cap 0.07 0.21 1 g every 8 21 x 500 mg cap 0.07 0.42 0.5 g every 8 250mg/5 ml 100 ml (5 1 g every 8 250 mg/5 ml 100ml (5 0.5 g every 8 250 mg/5 ml SF, 100 ml (5 1 g every 8 250 mg/5 ml SF, 100 ml (5 1.20 0.36 1.20 0.72 1.42 0.43 1.42 0.85 Broad spectrum beta-lactamase stable penicillin 5

Co-amoxiclav 250/125 mg every 8 500/125 mg every 8 Flucloxacillin 250 mg every 6 Co-fluampicil Cephalosporin 1st generation 250 mg every 6 250 mg every 6 250 mg/250 mg every 6 500 mg/500 mg every 6 250 mg/250 mg every 6 500 mg/500 mg every 6 Cefalexin 250 mg every 6 500 mg every 8 21 x 250/125 mg tab 21 x 500/125 mg tab 28 x 500 mg 250 mg/5 ml 100 ml (5 250 mg/5 ml 100 ml (5 250 mg/5 ml SF, 100 ml (5 250 mg/5 ml SF, 100 ml (5 28 x 250/250 mg 28 x 250/250 mg 125/125 mg per 5 ml, powder for 100 ml (2.5 125/125 mg per 5 ml, powder for 100 ml (2.5 0.27 0.82 0.34 1.02 0.06 0.25 0.09 0.36 26.28 5.26 26.28 10.51 26.87 5.37 26.87 10.75 0.20 0.78 0.20 1.56 22.86 9.14 22.86 18.29 tab 0.08 0.32 21 x 500 mg tab 0.13 0.40 1 g every 6 21 x 500 mg tab 0.13 1.07 1 g every 8 21 x 500 mg tab 0.13 0.80 1.5 g every 6 21 x 500 mg tab 0.13 1.60 1.5g every 8 21 x 500 mg tab 0.13 1.20 250 mg every 6 500 mg every 8 21 x 500 mg 1 g every 6 21 x 500 mg 0.07 0.28 0.10 0.30 0.10 0.80 1 g every 8 21 x 500 mg 0.10 0.60 6

1.5 g every 6 21 x 500 mg 1.5 g every 8 21 x 500 mg 250 mg every 6 500 mg every 8 Cefradine 250 mg every 6 125 mg/5 ml oral suspension, 100 ml (2.5 250 mg/5 ml oral suspension, 100 ml (5 1 g every 6 250 mg/5 ml oral suspension, 100 ml (5 1 g every 8 250mg/5ml oral suspension, 100ml (5 1.5 g every 6 250mg/5ml oral suspension, 100ml (5 1.5 g every 8 250mg/5ml oral suspension, 100ml (5 20 x 250 mg 20 x 500 mg 1 g every 6 20 x 500 mg 250 mg every 6 Cefadroxil 500 mg every 12 Cephalosporin 2nd generation Cefaclor 250 mg every 8 250 mg/5 ml, powder for susp, 100 ml (5 250 mg/5 ml, powder for susp, 100 ml (5 1 g every 6 250 mg/5 ml, powder for susp, 100 ml (5 20 x 500 mg 1 g every 12 20 x 500 mg 500 mg every 8 21 x 250 mg 21 x 250 mg 0.10 1.20 0.10 0.90 1.50 0.60 1.79 0.54 1.79 1.43 1.79 1.07 1.79 2.15 1.79 1.61 0.14 0.57 0.26 1.03 0.26 2.05 3.77 0.75 3.77 1.51 3.77 3.02 1.00 1.99 1.00 3.99 0.30 0.91 0.30 1.82 7

Distaclor MR Flynn Pharma Ltd 750 mg every 12 w food Distaclor 500 mg every 8 Cefuroxime Zinnat GSK 500 mg every 12 Cephalosporin 3rd generation 14 x 375 mg tablets 250 mg/5 ml, powder for susp, 100 ml (5 0.65 2.60 8.26 2.48 14 x 250 mg tab 0.76 3.04 Cefixime Suprax Sanofi 200 mg daily 7 x 200 mg tab 1.89 1.89 400 mg daily 7 x 200 mg tab 1.89 3.78 Cefpodoxime Orelox Sanofi 100 mg once daily 10 x 100 mg tab 0.98 0.98 Fluoroquinolones 1st and 2nd generation Ciprofloxacin 500 mg every 12 100 mg twice daily 10 x 100 mg tab 0.98 1.96 200 mg once daily 10 x 100 mg tab 0.98 1.96 200 mg twice daily 10 x 100 mg tab 0.98 3.91 750 mg every 12 20 x 500 mg tab 0.07 0.14 20 x 500 mg tab + 20 x 250 mg tab 0.12 0.25 Ofloxacin Tarivid Sanofi 400 mg once daily 10 x 400 mg tab 1.50 1.50 3rd and 4th generation 400 mg twice daily 10 x 400 mg tab 1.50 3.00 Levofloxacin 500 mg once daily 10 x 500 mg tab 2.02 2.02 500 mg twice daily 10 x 500 mg tab 2.02 4.03 Moxifloxacin Avelox Bayer 400 mg once daily 5 x 400 mg tab 2.49 2.49 Macrolides Clarithromycin 500 mg every 12 Clindamycin 150 mg every 6 Dalacin C Pharmaci a 300 mg every 6 450mg every 6 150 mg every 6 300 mg every 6 450 mg every 6 Erythromycin 250 mg every 6 14 x 500 mg tab 0.23 0.47 24 x 150 mg 24 x 150 mg 24 x 150 mg 24 x 150 mg 24 x 150 mg 24 x 150 mg 0.31 1.25 0.31 2.51 0.31 3.76 13.72 27.44 0.57 2.29 0.57 4.57 tab 0.06 0.25 8

0.5 g every 12 tab 0.06 0.51 tab 0.06 0.25 1 g every 12 tab 0.06 0.51 250 mg every 6 0.29 1.16 0.29 2.31 0.5 g every 12 0.29 1.16 1 g every 12 0.29 2.31 Azithromycin 500 mg once daily 3 x 500 mg tab 0.85 0.85 Tetracycline Doxycycline 200 mg daily 50 x 100 mg Vibramyc in-d Pfizer 200 mg daily 8 x 100 mg dispensable tab Tetracycline 250 mg every 6 500 mg every 8 Minocycline 100 mg every 12 a) BNF 65{Joint Formulary Committee, 2013 BNF2013 /id} a)b) MIMS, April 2013{2013 MIMS /id} tabs tabs tabs 28 x 100 mg tabs 0.06 0.06 0.61 0.61 0.24 0.98 0.24 1.47 0.24 1.96 0.48 0.96 Table 2 - cost of intravenous therapy for pneumonia Beta-lactams Narrow-spectrum class 1 Penicillin G 0.6 g every 6 25 x 0.6 g vial 0.95 3.80 Narrow spectrum class 2 Amoxicillin Amoxil GSK 0.5 g every 8 (IM or IV) 1.2 g every 6 25 x 1.2 g vial 1.89 7.56 1 g every 6 Broad-spectrum beta-lactamase stable penicillin Co-amoxiclav Augment in 10 x 500 mg powder in vial 10 x 1 g powder in vial GSK 1.2 g every 8 10 x 1.2 g(1 g/200 m powder in vial 0.55 1.64 1.10 4.38 1.06 3.18 9

Piperacillin/ tazobactam Clavulanic acid/ticarcillin Co-fluampicil Tazocin Pfizer 4.5 g every 8 Magnape n Cephalosporin 2nd generation Wockhar dt UK Ltd 4.5 g every 6 3.2 g every 8 3.2 g every 6 250 mg/250 mg every 6 500 mg/500 mg every 6 250 mg/250 mg every 6 Cefuroxime Zinacef GSK 750 mg every 6 Cephalosporin 3rd generation Cefotaxime 750 mg every 8 4.5 g (4 g/500 powder in vial 4.5 g (4 g/500 powder in vial 3.2 g (200mg/3 powder in vial 4 x 3.2 g (200 mg/3 powder in vial 125/125 mg per 5 ml, powder for 100 ml (2.5 125/125 mg per 5 ml, powder for 100 ml (2.5 10 x 250/250 mg powder in vial 15.17 45.51 15.17 60.68 5.33 15.99 5.33 21.32 22.86 9.14 22.86 18.29 1.33 5.33 750 mg vial 2.34 9.36 750 mg vial 2.34 7.02 1.5 g every 6 1.5 g vial 4.70 18.80 1.5 g every 8 1.5 g vial 4.70 14.10 1 g every 12 2 g every 6 1 g vial 4.31 8.62 2 g vial 8.57 34.28 Ceftriaxone Rocephin Roche 1 g daily 1 g vial 9.58 9.58 Ceftazidime Kefadim Flynn Pharma Ltd Cephalosporin 5th generation Ceftaroline fosamil Carbapenem Zinforo AstraZan eca 2 g daily 2 g vial 19.18 19.18 4 g daily (IV 2 g vial 19.18 38.36 1 g every 8 2 g every 8 600 mg every 12 Imipenem 1 g every 8 1 g vial 7.92 23.76 2 g vial 15.84 47.52 600 mg vial 37.50 75.00 500 mg vial 12.00 48.00 500 mg vial 12.00 72.00 10

Primaxin MSD 1 g every 8 Meropenem 500 mg every 8 1 g every 8 500 mg vial 12.00 48.00 500 mg vial 12.00 72.00 500 mg powder in vial 1 g powder in vial Ertapenem Invanz Merck 1 g once daily 1 g powder in vial Fluoroquinolones 1st and 2nd generation Ciprofloxacin 400 mg every 8 400 mg every 12 Ciproxin Bayer 400 mg every 8 400 mg every 12 Ofloxacin Tarivid Sanofi 200 mg twice daily 3rd and 4th generation Levofloxacin 500 mg once daily 2 mg/ml, 200 ml (400 m 2 mg/ml, 200 ml (400 m 2 mg/ml, 200 ml (400 m 2 mg/ml, 200 ml (400 m 2 mg/ml, 100 ml (200 m 5 mg/ml, 100 ml (500 m 8.00 24.00 16.00 48.00 31.65 31.65 22.00 66.00 22.00 44.00 22.85 68.55 22.85 45.70 16.16 32.32 26.40 26.40 500 mg twice daily Tavonic Sanofi 500 mg once daily 500 mg twice daily Moxifloxacin Avelox Bayer 400 mg once daily Macrolides Clarithromycin Klaricid Abbott 500 mg every 12 Clindamycin Dalacin C Pharmaci a 5 mg/ml, 100 ml (500 m 5 mg/ml, 100 ml (500 m 5 mg/ml, 100 ml (500 m 5 x 400 mg bottle 500 mg powder in vial 0.6 g daily 5 x 4 ml ampules (150 mg/ml) (600 m 2.4 g daily 5 x 4 ml ampules (150 mg/ml) (600 m 4.8 g daily 5 x 4 ml ampules (150 mg/ml) (600 26.40 52.80 26.40 26.40 26.40 52.80 39.95 39.95 9.45 18.90 12.35 12.35 12.35 49.40 12.35 98.80 11

Erythomycin Erythroci n m Amdipha rm 12.5 mg/kg every 6 1 g in vial 10.98 43.92 Azithromycin (c) Zedbac Aspire Pharma 500 mg daily 500 mg in powder in vial 9.50 9.50 Formatted: Font: 10 pt, a) BNF 65{Joint Formulary Committee, 2013 BNF2013 /id} b) MIMS, April 2013{2013 MIMS /id} (c) MIMS, August 2014 Comment [EF1]: Need to add to RefMan Formatted: Numbered + Level: 1 + Numbering Style: a, b, c, + Start at: 3 + Alignment: Left + Aligned at: 0 cm + Indent at: 0.5 cm Formatted: Normal,~BodyText, No bullets or numbering 12

Table 3: Glucocorticosteroid unit costs Dose available Cost (a) Cost per tab Dexamethasone 0.5 mg 38.00 1.36 2 mg 6.77 0.14 2 mg 13.09 0.13 150 ml (Oral Solution) 42.30-1 ml (4 m (Injection) 0.83 - Not Italic, Font color: Text 1, Hydrocortisone 10 mg 43.13 1.44 20 mg 45.93 1.53 1 ml (100 m (Injection) 1.08-5 ml (500 m (Injection) 4.89-100 mg (Injection) 0.92-100 mg + 2 ml water (Injection) 1.16 - Methyl-prednisolone 2 mg 3.88 0.13 4 mg 6.19 0.21 16 mg 17.17 0.57 100 mg 48.32 2.42 40 mg (Injection) 1.58-125 mg (Injection) 4.75-500 mg (Injection) 9.60-1 g (Injection) 17.30-2 g (Injection) 32.86 - Prednisolone 1 mg 1.18 0.04 5 mg 1.21 0.04 25 mg 30.00 0.54 2.5 mg (e/c) 10.03 0.36 2.5 mg (e/c) 30.79 0.31 5 mg (e/c) 9.86 0.35 5 mg (e/c) 31.04 0.31 5 mg (soluble) 9.65 0.32 a) MIMS, April 2013{2013 MIMS /id} 13

Table 4: Reviewed studies glucocorticosteroid costs Study Dose Total drug cost (a) per day Average drug cost Confalonieri 2005 1 Hydrocortisone 200 mg IV + 240 mg/day for 7 days Fernandez-Serrano 2011 2 Methyl-prednisolone 200 mg IV + 20 mg/6 h for 3 days; 20 mg/12 h for 3 days; 20 mg/day for 3 days 17.48 2.50 24.49 2.72 Marik 1993 3 Hydrocortisone 10 mg/kg N/A N/A McHardy 1972 4 Prednisolone 20 mg/day oral for 7 days Meijvis 2011 5 Dexamethasone 5 mg IV/day for 4 days Sabry 2011 6 Hydrocortisone 200 mg IV + 12.5 mg/h IV for 7 days 1.12 0.16 16.60 4.15 26.68 3.81 Snijders 2010 7 Prednisolone (c) 40 mg IV or oral for 7 days 10.29/ 2.24 1.47/ 0.32 (a) These costs do not include costs of antibiotics, equipment, preparations or staff time; they are based on the unit cost presented on Table 3 IV prednisolone is not routinely available. Equivalent doses and costs of IV hydrocortisone are used instead (c) IV costs are those for hydrocortisone, oral costs are those for prednisolone Formatted: Font: 10 pt, Not Italic, Formatted: Font: 10 pt, Not Italic, 14

Error! No text of specified style in document. 2 References 1 Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. American Journal of Respiratory and Critical Care Medicine. 2005; 171(3):242-248 2 Fernandez-Serrano S, Dorca J, Garcia-Vidal C, Fernandez-Sabe N, Carratala J, Fernandez-Aguera A et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Critical Care. 2011; 15(2):R96 3 Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest. 1993; 104(2):389-392 4 McHardy VU, Schonell ME. Ampicillin dosage and use of prednisolone in treatment of pneumonia: co-operative controlled trial. BMJ. 1972; 4(5840):569-573 5 Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011; 377(9782):2023-2030 6 Sabry NA, Omar EE-D. Corticosteroids and ICU Course of Community Acquired Pneumonia in Egyptian Settings. Pharmacology and Pharmacy. 2011; 2(2):73-81 7 Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. American Journal of Respiratory and Critical Care Medicine. 2010; 181(9):975-982 15